Jacobs Levy Equity Management
QNCX icon

Jacobs Levy Equity Management’s Quince Therapeutics QNCX Stock Holding History

Jacobs Levy Equity Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,445
Closed -$650K – 1023
2022
Q3 		$650K Buy
+2,445
New +$931K 0.01% 790

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jacobs Levy Equity Management's QNCX Position: Q4 2022 in Review

Jacobs Levy Equity Management sold out of Quince Therapeutics (QNCX) in Q4 2022, closing a stake of 2,445 shares — an estimated $650K sold.

Jacobs Levy Equity Management first reported a position in QNCX in Q3 2022 and held it in 1 quarter. The position peaked at $650K in Q3 2022. 48 funds tracked by Wall St. Rank hold QNCX as of Q4 2022.

  • Jacobs Levy Equity Management reported no remaining Quince Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 2,445 Quince Therapeutics shares in Q4 2022, an estimated $650K.
  • Jacobs Levy Equity Management first reported a position in Quince Therapeutics in Q3 2022 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Quince Therapeutics position peaked at $650K in Q3 2022.
  • 48 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.